Mizuho reports 2,000,000 DMAA shares (6.0%)

Mizuho Financial Group, Inc. filed a Schedule 13G reporting beneficial ownership of 2,000,000 common shares of Drugs Made In America Acquisition Corp. (CUSIP G2847J104), representing 6.0% of the class.

Rhea-AI Filing Summary

Mizuho Financial Group, Inc. filed a Schedule 13G reporting beneficial ownership of 2,000,000 common shares of Drugs Made In America Acquisition Corp. (CUSIP G2847J104), representing 6.0% of the class. The filing, signed by Takahiro Katsura, is dated 05/14/2026.

Insights

Institutional Ownership Analyst

Mizuho discloses a passive 6.0% stake in DMAA via Schedule 13G.

Mizuho Financial Group reports beneficial ownership of 2,000,000 shares of DMAA, representing 6.0%. The filing classifies the holding under a Schedule 13G disclosure, which typically indicates passive intent rather than active control.

Ownership is recorded through affiliated entities as described in the filing; subsequent filings would show any change in status or percentage.

Corporate Governance Specialist

This filing documents a parent holding declaration and identifies the subsidiary holding the securities.

The Schedule 13G includes a parent/ subsidiary disclosure noting that Mizuho Securities USA LLC holds the shares and that Mizuho Bank and affiliated entities may be deemed indirect beneficial owners. The signature certifies comparability of the foreign regulatory scheme.

Stake disclosures like this affect public visibility of institutional shareholders; any material increase would require updated reporting.

Key Figures

Beneficial ownership: 2,000,000 shares Percent of class: 6.0% CUSIP: G2847J104

3 metrics

Beneficial ownership 2,000,000 shares Common Shares of Drugs Made In America Acquisition Corp.

Percent of class 6.0% Percent of common shares outstanding reported in Schedule 13G

CUSIP G2847J104 Identifier for DMAA common shares as stated in filing

Key Terms

Schedule 13G, Beneficial ownership, Parent Holding Company

3 terms

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Amount beneficially owned: 2,000,000 (b) Percent of class: 6.0 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Parent Holding Company regulatory

"Parent Holding Company Item 4. | Ownership (a) | Amount beneficially owned"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mizuho's Schedule 13G filing for DMAA mean?

It reports a passive beneficial ownership stake of 2,000,000 shares (6.0%). The filing indicates Mizuho holds the shares via affiliated entities and classifies the position under Schedule 13G rather than an active Schedule 13D filing.

How large is Mizuho's stake in Drugs Made In America Acquisition Corp. (DMAA)?

Mizuho beneficially owns 2,000,000 common shares, equal to 6.0% of the class. The CUSIP cited is G2847J104 and the filing is signed on 05/14/2026 by a Mizuho managing director.

Who within Mizuho signed the DMAA ownership disclosure?

Takahiro Katsura, Managing Director, signed the filing on 05/14/2026. The filing includes a parent holding company declaration and an exhibit reference identifying the subsidiary holding the securities.

Does this Schedule 13G indicate Mizuho controls DMAA?

No. The Schedule 13G reports a passive beneficial ownership position of 6.0%. The filing notes affiliation and indirect ownership via Mizuho Securities USA LLC but does not claim control or active solicitation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 06:32 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Drugs Made In America Acquisition Corp.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

G2847J104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G2847J104

1

Names of Reporting Persons

Mizuho Financial Group, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

JAPAN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,000,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,000,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,000,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Drugs Made In America Acquisition Corp.
(b)	Address of issuer's principal executive offices: 420 Lexington Avenue, Suite 1402, New York, NY 10170
Item 2.
(a)	Name of person filing: Mizuho Financial Group, Inc.
(b)	Address or principal business office or, if none, residence: 1-5-5, Otemachi, Chiyoda-ku, Tokyo, 100-8176, Japan
(c)	Citizenship: Japan
(d)	Title of class of securities: Common Shares
(e)	CUSIP Number(s): G2847J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Parent Holding Company
Item 4.	Ownership
(a)	Amount beneficially owned: 2,000,000
(b)	Percent of class: 6.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,000,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,000,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit A
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Parent Holding Company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mizuho Financial Group, Inc.

Signature:	/s/ Takahiro Katsura
Name/Title:	Takahiro Katsura, Managing Director, Global Corporate Function Coordination Department
Date:	05/14/2026